Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Accumulated Expenses (2019 - 2025)

Harmony Biosciences Holdings' Accumulated Expenses history spans 7 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 88.54% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, down 88.54%, while the annual FY2025 figure was $2.2 million, 88.54% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $2.2 million at Harmony Biosciences Holdings, down from $2.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $45.6 million in Q2 2022 and bottomed at $1.1 million in Q1 2023.
  • The 5-year median for Accumulated Expenses is $7.4 million (2024), against an average of $11.4 million.
  • The largest YoY upside for Accumulated Expenses was 1175.37% in 2023 against a maximum downside of 95.68% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $2.1 million in 2021, then skyrocketed by 442.68% to $11.5 million in 2022, then surged by 105.92% to $23.7 million in 2023, then decreased by 20.93% to $18.8 million in 2024, then plummeted by 88.54% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Accumulated Expenses are $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $2.3 million (Q2 2025).